There is a paucity of literature addressing infection-related morbidity and mortality in children with primary hemophagocytic lymphohistiocytosis (HLH), a rare condition characterized by abnormal proliferation of macrophages, hypercytokinemia, and T cell immunosuppression. Therefore, a retrospective chart review was done of patients diagnosed with primary HLH over a 15-year period. Significant infections present at diagnosis, during the course of illness, and just prior to death or at autopsy were noted. Of the 18 children identified with primary HLH, an infectious agent was documented at the initial presentation of HLH in 5. Significant infections occurred during therapy in 10 (56%) of 18. Of the 12 fatal cases, invasive infection was the cause of death in 8 children, and 6 of these deaths were directly attributable to invasive fungal infection. Significant infections were common during therapy in children with primary HLH, and fungal infections were an important cause of mortality in this group.
Infections are also a significant source of morbidity and mortality in this disease. Infectious complications in primary HLH are not unexpected, given that these children are profoundly immunosuppressed, both by the disease itself and by the chemotherapy directed at the disease. Despite this profound immunosuppression, there are almost no reports that have addressed the nature of infectious complications in primary HLH and the specific role of infections in fatal cases. Understanding these complications may allow prophylactic or preemptive strategies that may improve the prognosis of this frequently fatal disease. The purpose of this review was to examine the role of infections throughout the course in children diagnosed with primary HLH.
MATERIALS AND METHODS
The medical records of children treated at the Hospital for Sick Children (Toronto) from January 1985 through June 2000 with a diagnosis of primary HLH were reviewed. The outcomes were infections present at diagnosis and during therapy and the role of infection in fatal cases. Children were included who fulfilled the criteria for HLH according to the Histiocyte Society diagnostic guidelines [1] . In brief, the diagnosis of primary HLH is fulfilled when all of the following criteria are met: fever, splenomegaly, cytopenia affecting at least 2 of 3 lineages in the peripheral blood, hypertriglyceridemia, and/or hypofibrinogenemia and hemophagocytosis in bone marrow, spleen, or lymph nodes without evidence of malignancy. Children with an underlying condition known to predispose to secondary HLH, such as malignancy, immunodeficiency, and rheumatic conditions, were excluded.
Significant infections were defined as microorganisms isolated from normally sterile sites or tissue culture. The cause of death was attributed to an infectious agent if a plausible agent was obtained from a normally sterile site or biopsy material just prior to death or if a microorganism was isolated from multiple tissues at autopsy. Attributing death to progressive HLH was accomplished by the clinical impression at the time of death or autopsy findings if available. Descriptive statistical analyses were performed with the use of Statistical Package for the Social Sciences (SPSS version 10).
RESULTS
During the study period, 18 children were diagnosed with primary HLH. A family history of HLH was found in 4 children (22%), and consanguinity was noted in the parents of 1 child. Table 1 illustrates the clinical features of these patients at diagnosis. The median time between presentation to hospital and diagnosis was 2 weeks (range, 1 day-20 weeks). The median follow-up time for survivors was 3.9 years (25th, 75th percentile, 1.4, 7.4 years), and that for fatal cases was 2.3 months (25th, 75th percentile, 17 days, 1.7 years). Hemophagocytosis, as defined by engulfment of erythrocytes and other hematopoietic cells by macrophages, was documented in bone marrow examinations of all children.
In the 1 month prior to presentation, a clinical history of a viral infection was elicited in 5 (28%) children, and 4 (22%) received immunizations consisting of the primary series of diphtheria, tetanus, and pertussis vaccine. A microorganism was documented at diagnosis in 5 cases. In 2 cases, EpsteinBarr virus infection (EBV) infection was noted. In 1 case, EBV was diagnosed by an elevated IgM and IgG to the viral capsid antigen (VCA), whereas a second case was documented by EBV DNA detected in serum by PCR associated with a positive IgG to EBV VCA (IgM was not measured). Cytomegalovirus (CMV) was cultured from urine at presentation in 1 rapidly fatal case; CMV was also isolated from lungs at autopsy. Enterovirus was cultured from a nasopharyngeal swab in 1 case, and Mycoplasma pneumoniae complement fixation titer was у1:128 in another child.
Seventeen children received chemotherapy; 15 (88%) of 17 regimens included systemic corticosteroid therapy. Intravenous immunoglobulin was used in only 1 child; in that case, it was used to treat EBV disease rather than as specific HLH-directed therapy. Two children underwent matched sibling-donor bone marrow transplantation (BMT), and both are long-term survivors.
Significant infections occurred on therapy in 10 (56%) of 18 children (table 2) . Case number 16 had several significant infections. After 8 months of HLH-directed therapy, he developed Pseudomonas aeruginosa bacteremia and meningitis. Soon after recovering from this infection, he was found to have Streptococcus pneumoniae bacteremia. His chemotherapy was stopped prematurely after 15 months because of concerns of toxicity; his parents also refused BMT from his matched sibling. He subsequently developed a second invasive pneumococcal infection with bacteremia and meningitis 4 months after cessation of chemotherapy. The patient remains in complete remission 14 months after discontinuation of chemotherapy, although he has significant developmental delay.
For the entire cohort, survival was 26% at 5 years by Kaplan Meier analysis. Of the 12 fatal cases, 8 (67%) underwent autopsy. The cause of death was clinically diagnosed (2 cases) or pathologically confirmed (2 cases) progressive HLH in 4 children. In the remaining 8 children, the cause of death was invasive infection (table 2) . Disseminated CMV and Enterobacter sepsis were the cause of death in 2 children. In 6 patients (50% of fatal cases), the cause of death was directly attributable to invasive fungal infection: 2 patients with invasive aspergillosis, 3 patients with disseminated candidiasis, and 1 patient in which both Fusarium species in a blood culture and Aspergillus species from the oral palate were isolated. Amphotericin B was used treat all invasive fungal infections, except for patients 3, 5, and 15, in which the infections were not identified until after death. Active hemophagocytosis was seen at autopsy in all children who died of infection, with the exception of 1 child, who died of disseminated candidiasis. In the 8 children whose deaths were infection-related, the median time between diagnosis and death was 67 days (25th, 75th percentile: 15 days, 1.7 years). Of these 8 children, 7 were receiving HLH-directed therapy just prior to death; the one untreated child was patient 9, who rapidly succumbed to CMV infection. It is unclear why patient 18 survived her invasive fungal infection with candidemia, compared with the fatal cases of invasive fungal infection. The positive blood culture for Candida albicans occurred 12 days after initiation of chemotherapy, at a time when she was profoundly neutropenic, with an absolute neutrophil count of 9 cells/L. She received prompt amphotericin B at diag-0 ϫ 10 nosis of the candidemia, her central venous line was removed, and the neutropenia resolved 15 days later.
DISCUSSION
Infections play a significant role throughout the course of children diagnosed with primary HLH; the infectious disease consultant is likely to be involved in every stage of disease. However, primary HLH is rare, with an incidence of ∼1 in 50,000 live births [2] , which thus leads to unfamiliarity with this disease entity. The importance of infections in this disease, combined with the rarity of illness and the paucity of information in the literature aimed at the role of infections in primary HLH, provided the rationale for this review.
HLH is conventionally divided into primary and secondary forms. In primary disease, a cause is not identified and includes familial HLH (FHLH or FHL). FHLH is an autosomal recessive disorder [3] with an increased incidence noted in children from consanguineous parents. However, sporadic mutations are common; thus, the absence of a family history or consanguinity does not rule out disease. Although most patients develop FHLH prior to the first year of life [4] , familial forms have been reported up to age 8 years [4] , and, to date, no upper age limit has been defined. Without treatment, FHLH is usually fatal, with a median survival of 2 months [5] . Chemotherapy improves the course of FHLH, although the only known curative therapy is allogeneic BMT [6] [7] [8] [9] . Secondary HLH implies an acquired cause and is the result of strong immunologic activation that typically occurs in an immunocompromised host. Triggers of secondary HLH include infection [1, 10] , malignancy [1] , and iv administration of soluble lipids [1] .
For most children, it is impossible to distinguish between primary HLH with an infectious trigger and secondary HLH related to infection in the absence of known predisposing factors. A family history or consanguinity implies FHLH, whereas the development of HLH in the setting of immunodeficiency, malignancy, or rheumatic condition defines secondary disease. Previously well children who fulfill criteria for HLH are usually classified as primary HLH irrespective of whether an infection is identified at the onset of disease. This practice is justified by the uniformly poor survival regardless of whether or not an infectious trigger is identified [4] .
Microbiologic documentation at diagnosis was found in 28% in this series. This percentage is similar to the 22% reported to an International Registry [4] ; the spectrum of microorganisms in this study was also similar to that found in the Registry. Nonetheless, because a rigorous systematic search for a microorganism was not performed at presentation of primary HLH, these estimates likely underestimate the contribution of microbiologic triggers to HLH. A broad range of organisms has been associated with HLH in previous reports, including several viruses, bacteria, fungi, and parasites [11] . Multiple organisms have been implicated in some cases [12] . In our series, a history of a clinical viral syndrome was noted in 28%, and immunization was noted in 22% during the month preceding presentation. This finding may be a reflection of the typical age of diagnosis combined with recall bias rather than a significant finding in itself. Nonetheless, further exploration of this observation may help to clarify the roles of these potential triggers of HLH.
Significant infections were noted in 56% of children while they were receiving chemotherapy for HLH, and 67% percent of fatal cases could be directly attributable to invasive infection. Also noteworthy was the high incidence of fatal fungal infection, which occurred in 50% of fatal cases. These significant infections are likely related to the profound immunosuppression in children with primary HLH, which is both related to their underlying disease and the HLH-directed chemotherapy. At presentation, almost all children with primary HLH are neutropenic; this neutropenia usually persists until successful therapy has been instituted. Combined with neutropenia is a defect in the cellular immune system. NK cell activity and T cell cytotoxicity are low or absent in HLH [13] , and a defect in perforin, which is fundamental to cytotoxic T cell activity, has been demonstrated to be the underlying defect in some cases of FHLH [14] . This profound immunosuppression is worsened by chemotherapy, which causes significant cellular and phagocytic immune dysfunction.
The importance of infections in fatal cases of HLH has not been previously emphasized. In the majority of series, the cause of death has been primarily ascribed to progressive and/or relapsed HLH [4, [15] [16] [17] . However, one series reported 4 of 6 fatal cases being related to opportunistic infection [18] . It is likely, though, that deaths due to fungal infection are underreported. In fact, within our series, 2 children were found to have died from invasive fungal infection only at autopsy; their deaths would have been ascribed to progressive HLH had an autopsy not been undertaken.
Given the importance of infections in children with primary HLH, we suggest vigilance when these children become febrile, both at initial presentation and during active therapy. Additionally, antifungal therapy in prolonged febrile neutropenia is warranted. Finally, we suggest that antifungal prophylaxis be considered in children undergoing active therapy for primary HLH.
CONCLUSION
Infections play an important role throughout the course of a child diagnosed with primary HLH. Initial presentation may mimic severe viral infections, and viral infections are a common trigger of HLH. In our series, a microorganism was documented in 5 (28%) of 18 children at the initial diagnosis of primary HLH. Significant infections were common during the course of HLH-directed therapy, and these infections may be recurrent, even after cessation of therapy. Finally, infections were important contributors to mortality, accounting for 8 (67%) of 12 deaths, with invasive fungal infections causing 6 (50%) of 12 fatal cases. Infectious Disease clinicians who care for children should be familiar with the role of infections throughout the course of disease in primary HLH.
